Form 4: ImmunityBio Director Granted Significant Stock Options Under 2025 Equity Incentive Plan

ImmunityBio, Inc. has reported that Director Christobel Selecky was granted 162,786 stock options with an exercise price of $2.84, vesting by June 2026.

Summary

• Christobel Selecky, a Director of ImmunityBio, Inc. (IBRX), was granted 162,786 stock options.
• The options have an exercise price of $2.84 per share.
• The grant date for these options was June 18, 2025.
• The options are set to expire on June 18, 2035.
• One hundred percent (100%) of the shares subject to the award will vest on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Ms. Selecky's continued service as a Service Provider, as defined in the Issuer's 2025 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a Form 4 is primarily a factual disclosure, the grant of options to a director indicates continued commitment and aligns interests, which is generally viewed favorably. There are no negative financial implications or significant risks disclosed.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value, as the options gain value if the stock price increases.
• The options are granted under the Issuer's 2025 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though this is a standard aspect of equity compensation plans.

Risks

• The vesting of the stock options is subject to the reporting person's continuing to be a 'Service Provider' through the applicable vesting date, meaning the options could be forfeited if the service relationship ceases before vesting.

Future Outlook

The document primarily reports a past transaction (option grant) and its future vesting schedule, rather than providing forward-looking statements on company performance or guidance.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industry, where equity-based compensation, such as stock options, is a common tool to attract, retain, and incentivize directors and key personnel, aligning their interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a common compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, where long-term incentives are crucial.
• The vesting schedule, tied to continued service and a specific future date or corporate event (annual meeting), is typical for such grants, similar to those observed at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors.
• The exercise price being set at the market price on the grant date ($2.84) is standard for incentive stock options, ensuring that the director benefits only if the company's stock price appreciates from that point.

Corporate Governance

Related Party Transactions

• The transaction involves a stock option grant from ImmunityBio, Inc. to Christobel Selecky, a Director of the company. This is a direct transaction between the company and an insider.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from aligned director incentives for long-term stock price appreciation.
• Director (Christobel Selecky): Receives a significant equity incentive, aligning personal financial interests with the company's performance.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the date immediately preceding ImmunityBio's next annual meeting of stockholders, provided Christobel Selecky continues as a Service Provider.

Key Dates

Keywords

ImmunityBio, IBRX, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Incentive Plan, Beneficial Ownership, Christobel Selecky